Cargando…

Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020

This cross-sectional study investigates the representation status of Black US residents in clinical trials of 24 cardiovascular drugs granted US Food and Drug Administration (FDA) approval between January 1, 2006, and August 31, 2020.

Detalles Bibliográficos
Autores principales:	Chen, Siliang, Li, Jiarui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988366/ https://www.ncbi.nlm.nih.gov/pubmed/33755163 http://dx.doi.org/10.1001/jamanetworkopen.2021.2640

Ejemplares similares

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality
por: Tamatam, Rekha, et al.
Publicado: (2023)

Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020
por: Lythgoe, M. P., et al.
Publicado: (2021)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

Use of surrogate outcomes in US FDA drug approvals, 2003–2012: a survey
por: Yu, Tsung, et al.
Publicado: (2015)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018
por: Ribeiro, Tatiane Bomfim, et al.
Publicado: (2020)

US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives
por: Wang, Shawn Shouye, et al.
Publicado: (2021)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

Older U.S. Adults With Nocturia Often Cannot Use the Only FDA-Approved Drugs for the Condition
por: Johnson, Theodore, et al.
Publicado: (2020)

Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020
por: Zhang, Audrey D., et al.
Publicado: (2021)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

US FDA Drug Approvals are Persistent and Polycyclic: Insights into Economic Cycles, Innovation Dynamics, and National Policy
por: Daizadeh, Iraj
Publicado: (2021)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

Water Networks in Complexes between Proteins and FDA-Approved Drugs
por: Samways, Marley L., et al.
Publicado: (2022)

Ebanga™: The most recent FDA-approved drug for treating Ebola
por: Taki, Elahe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9j93l25vc28jvvoa6kll0te0uh